Ferulic acid in combination with PARP inhibitor sensitizes breast cancer cells as chemotherapeutic strategy

Biochemical and Biophysical Research Communications

Volumn 458, Issue 3, 2015, Pages 520-524

  Choi, Young Eun ^a   Park, Eunmi ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Department of Food and Nutrition School of Life Science and Nano Technology Hannam University   (United States)

Author keywords

ABT 888; Breast cancer cells; Ferulic acid; Homologous recombination repair

Indexed keywords

BRCA1 PROTEIN; FERULIC ACID; HISTONE H2AX; PROTEIN; RAD51 PROTEIN; UAF1 PROTEIN; UNCLASSIFIED DRUG; VELIPARIB; ANTINEOPLASTIC AGENT; ANTIOXIDANT; BENZIMIDAZOLE DERIVATIVE; COUMARIC ACID; ENZYME INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE;

ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CELL SURVIVAL; CHEMOSENSITIVITY; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DOUBLE STRANDED DNA BREAK; DRUG ACTIVITY; HOMOLOGOUS RECOMBINATION; MCF 7 CELL LINE; MDA MB 231 CELL LINE; MOUSE EMBRYO; PRIORITY JOURNAL; RECOMBINATION REPAIR; SENSITIZATION; U2OS CELL LINE; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; BREAST; BREAST NEOPLASMS; DRUG EFFECTS; FEMALE; GENETICS; HUMAN; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIOXIDANTS; BENZIMIDAZOLES; BREAST; BREAST NEOPLASMS; CELL LINE, TUMOR; COUMARIC ACIDS; DNA DAMAGE; ENZYME INHIBITORS; FEMALE; HUMANS; POLY(ADP-RIBOSE) POLYMERASES; RAD51 RECOMBINASE; RECOMBINATIONAL DNA REPAIR;

EID: 84924023229     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2015.01.147     Document Type: Article

References (18)

1. M.W. Audeh, J. Carmichael, R.T. Penson, M. Friedlander, B. Powell, K.M. Bell-McGuinn, C. Scott, J.N. Weitzel, A. Oaknin, and N. Loman Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial Lancet 376 2010 245 251
2. A. Bhattacharyya, U.S. Ear, B.H. Koller, R.R. Weichselbaum, and D.K. Bishop The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin J. Biol. Chem. 275 2000 23899 23903
3. H.E. Bryant, N. Schultz, H.D. Thomas, K.M. Parker, D. Flower, E. Lopez, S. Kyle, M. Meuth, N.J. Curtin, and T. Helleday Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase Nature 434 2005 913 917
4. Y.E. Choi, Y. Pan, E. Park, P. Konstantinopoulos, S. De, A. D'Andrea, and D. Chowdhury MicroRNAs down-regulate homologous recombination in the G1 phase of cycling cells to maintain genomic stability eLife 3 2014 e02445
5. Eitsuka, T., Tatewaki, N., Nishida, H., Kurata, T., Nakagawa, K., and Miyazawa, T. Synergistic inhibition of cancer cell proliferation with a combination of delta-tocotrienol and ferulic acid. Biochem. Biophys. Res. Commun. 453, 606-611.
6. H. Farmer, N. McCabe, C.J. Lord, A.N. Tutt, D.A. Johnson, T.B. Richardson, M. Santarosa, K.J. Dillon, I. Hickson, and C. Knights Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy Nature 434 2005 917 921
7. C. Jacquemont, J.A. Simon, A.D. D'Andrea, and T. Taniguchi Non-specific chemical inhibition of the Fanconi anemia pathway sensitizes cancer cells to cisplatin Mol. Cancer 11 2012 26
8. N. Johnson, Y.C. Li, Z.E. Walton, K.A. Cheng, D. Li, S.J. Rodig, L.A. Moreau, C. Unitt, R.T. Bronson, and H.D. Thomas Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition Nat. Med. 17 2011 875 882
9. K. Kawabata, T. Yamamoto, A. Hara, M. Shimizu, Y. Yamada, K. Matsunaga, T. Tanaka, and H. Mori Modifying effects of ferulic acid on azoxymethane-induced colon carcinogenesis in F344 rats Cancer Lett. 157 2000 15 21
10. Mancuso, C., and Santangelo, R. Ferulic acid: pharmacological and toxicological aspects. Food Chem. Toxicol. 65, 185-195.
11. M. Ohnishi, T. Matuo, T. Tsuno, A. Hosoda, E. Nomura, H. Taniguchi, H. Sasaki, and H. Morishita Antioxidant activity and hypoglycemic effect of ferulic acid in STZ-induced diabetic mice and KK-Ay mice Biofactors 21 2004 315 319
12. E. Park, J.M. Kim, B. Primack, D.M. Weinstock, L.A. Moreau, K. Parmar, and A.D. D'Andrea Inactivation of Uaf1 causes defective homologous recombination and early embryonic lethality in mice Mol. Cell. Biol. 33 2013 4360 4370
13. V.N. Perfilova, A.V. D'Iakova, and I.N. Tiurenkov Cardioprotective action of ferulic acid upon heart under stressor damage conditions Eksp. Klin. Farmakol. 68 2005 19 22
14. A.J. Pierce, P. Hu, M. Han, N. Ellis, and M. Jasin Ku DNA end-binding protein modulates homologous repair of double-strand breaks in mammalian cells Genes Dev. 15 2001 3237 3242
15. N. Turner, A. Tutt, and A. Ashworth Hallmarks of 'BRCAness' in sporadic cancers Nat. Rev. Cancer 4 2004 814 819
16. A. Tutt, M. Robson, J.E. Garber, S.M. Domchek, M.W. Audeh, J.N. Weitzel, M. Friedlander, B. Arun, N. Loman, and R.K. Schmutzler Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial Lancet 376 2010 235 244
17. D.M. Weinstock, K. Nakanishi, H.R. Helgadottir, and M. Jasin Assaying double-strand break repair pathway choice in mammalian cells using a targeted endonuclease or the RAG recombinase Methods Enzym. 409 2006 524 540
18. J.J. Yan, J.Y. Cho, H.S. Kim, K.L. Kim, J.S. Jung, S.O. Huh, H.W. Suh, Y.H. Kim, and D.K. Song Protection against beta-amyloid peptide toxicity in vivo with long-term administration of ferulic acid Br. J. Pharmacol. 133 2001 89 96